Investment: Few headaches for SKB
INVESTORS IN SmithKline Beecham need not reach for the company's anti-depressant, Paxil, for a good while yet. Forget all the noise about mega-mergers and the (unfounded) rumours about chief executive Jan Leschly's retirement plans - the pharmaceutical giant is good enough on its own.
Yesterday's third-quarter earnings are a case in point. Underlying profits rose 10 per cent to an expectation-busting pounds 415m, meeting SKB's target of double-digit earnings growth. Paxil was again the healthiest performer, with sales up 20 per cent. The antibiotic Augmentin, another big seller, bounced back from a rotten first half. Margins held firm, despite the company's increased spending on research and development - now a massive 18 per cent of sales.
On the minus side, turnover on over-the-counter drugs suffered from competitive pressures, while vaccines, an SKB strength, were down.
In the longer term, the problem will come in 2002, when SKB will lose patent protection on a number of money-spinners, including Augmentin. More worryingly, Paxil will go off-patent in 2005, with sales expected to drop by around 50 per cent almost immediately. But this is where SKB's huge R&D budget comes in - the money should speed up development of four products to plug the gaps.
The key is smooth approval for Avandia, a diabetes drug, which could be the next pharmaceutical blockbuster with estimated sales of $1bn (pounds 590m) a year. Progress is encouraging, with approval expected around the end of next year.
The rest of the pipeline looks fairly solid, and although earnings growth will be constrained by R&D spending, it will remain in double digits for the foreseeable future. The shares leapt 27.5p to 686p yesterday and now trade on 32 times 1998 earnings forecasts, a slight discount to Glaxo. Merger or no, SKB is a good long-term punt. Buy.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies